Quotient Investors LLC Continues to Hold Stake in Gilead Sciences, Inc. (GILD)

BidaskClub upgraded Gilead Sciences from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Jefferies maintained Gilead Sciences, Inc. Eventide Asset Management Llc sold 730,000 shares as Novavax Inc (NVAX)’s stock declined 31.13%. DRQ’s SI was 7.19M shares in August as released by FINRA.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, July 26th. It has underperformed by 38.50% the S&P500. (GILD) stake by 14.91% reported in 2016Q4 SEC filing. Ancora Advisors Ltd Liability Company accumulated 0.03% or 48,000 shares. The Westend Advisors Llc holds 735,033 shares with $52.64M value, down from 863,816 last quarter. Trimble Navigation Ltd now has $9.23 billion valuation.

The company is trading down by -0.43 percent from yesterday’s close. Insiders own 1.30% of the company’s stock. (NASDAQ:GILD) has declined 21.80% since August 11, 2016 and is downtrending. It has outperformed by 30.29% the S&P500. Mizuho maintained the shares of GILD in report on Tuesday, July 25 with “Buy” rating. Therefore 63% are positive. The company presently has a consensus rating of “Buy” and an average price target of $80.31. “Ultimately, through all this investigation into the company’s performance the analyst decides if their stock is a “buy”, sell” or hold”.

A number of equities research analysts recently commented on GILD shares. The rating was upgraded by Stifel Nicolaus on Thursday, October 22 to “Buy”. Finally, Piper Jaffray Companies reiterated a “buy” rating on shares of Gilead Sciences in a research note on Friday, April 21st. The company was maintained on Tuesday, July 25 by RBC Capital Markets. The firm earned “Market Perform” rating on Friday, December 4 by Wells Fargo. The firm has “Hold” rating by Maxim Group given on Friday, April 29.

Investors sentiment decreased to 0.7 in 2016 Q4. Its down 0.23, from 0.93 in 2016Q3. The shares were sold at an average price of $74.00, for a total value of $2,960,000.00. 45 funds opened positions while 69 raised stakes. 950.84 million shares or 0.69% more from 944.29 million shares in 2016Q3 were reported. Franklin Resources Inc. increased its position in Gilead Sciences by 2.2% in the fourth quarter. “(GILD)” was originally posted by Markets Daily and is owned by of Markets Daily. Cibc World Mkts accumulated 1.56M shares. Gilead Sciences’s payout ratio is now 22.58%. (GILD) has the trading volume of 8.65 Million shares with the average trading volume of 9480 shares. Market Capitalization if basically the market value of the company’s shares outstanding. California-based Kayne Anderson Rudnick Inv Management Limited Liability Com has invested 1.47% in Dril-Quip, Inc.

COPYRIGHT VIOLATION NOTICE: “FOURPOINTS Investment Managers S.A.S. Sells 6,400 Shares of Gilead Sciences, Inc”. Pioneer Investment invested 0.69% of its portfolio in Gilead Sciences, Inc. WILSON GAYLE E sold $1.41M worth of stock. Fisher Asset Limited Liability holds 0.06% or 455,496 shares in its portfolio.

Gilead Sciences, Inc.is a research biopharmaceutical firm that discovers, develops and commercializes medicines in areas of unmet medical need. Waddell & Reed Fincl holds 504,900 shares or 0.01% of its portfolio.

Gabelli Securities Inc increased Rite Aid Corp Com (RAD) stake by 3.16% reported in 2016Q4 SEC filing. Another trade for 5,000 shares valued at $341,529 was made by Alton Gregg H on Monday, May 1. Shares for $668,667 were sold by Cogan John Francis on Tuesday, May 9. Jefferies maintained Gilead Sciences, Inc. (NASDAQ:GILD) or 20,365 shares.

Mufg Americas Holdings Corp increased Ishares Tr (EEM) stake by 20,453 shares to 564,441 valued at $19.76 million in 2016Q4. It also upped Vanguard Ftse All World Ex (VEU) stake by 8,287 shares and now owns 125,227 shares. Thermo Fisher Scientific Inc (NYSE:TMO) was raised too.

Investors sentiment increased to 1.25 in 2016 Q4. Its up 0.11, from 0.75 in 2016Q3. Sell-side analyst recommendations point to a short term price target of $80.48 on the company shares. 118 funds opened positions while 208 raised stakes. Zurcher Kantonalbank (Zurich Cantonalbank) stated it has 5,789 shares or 0% of all its holdings. Lipe And Dalton reported 1.85% stake. 239,498 were accumulated by Herndon Capital Management Ltd Liability Company. Kbc Grp Inc Nv reported 0.02% in Trimble Inc (NASDAQ:TRMB). Washington Trust Bank owns 3,038 shares. Homrich And Berg invested in 0.02% or 3,537 shares. Bangor Bank & Trust invested in 13,799 shares. Ubs Asset Americas Inc has 0.07% invested in Trimble Inc (NASDAQ:TRMB) for 2.08 million shares. Its down 2.88% from 7.40 million shares previously. Moreover, Valley Natl Advisers Inc has 0.07% invested in Deere & Company (NYSE:DE). Sterling Capital Management Llc, a North Carolina-based fund reported 878,478 shares. Spears Abacus Advsrs Lc holds 52,000 shares or 0.2% of its portfolio. It uses profitability, leverage, liquidity, solvency and activity to forecast whether a company has a high degree of probability of being insolvent. Prudential holds 0% or 50,138 shares in its portfolio. Sei Investments Communications owns 380,778 shares. Wellington Mgmt Llp holds 11.06 million shares. Therefore 8% are positive. Novavax had 16 analyst reports since August 11, 2015 according to SRatingsIntel. As per Monday, September 12, the company rating was initiated by Berenberg. JP Morgan maintained the stock with “Overweight” rating in Friday, September 25 report. As per Thursday, September 22, the company rating was initiated by Berenberg. As per Thursday, November 5, the company rating was upgraded by Piper Jaffray. On Tuesday, June 28 the stock rating was downgraded by JP Morgan to “Neutral”. Ladenburg Thalmann downgraded Novavax, Inc.

Since February 22, 2017, it had 0 buys, and 8 insider sales for $16.50 million activity. $107,618 worth of Trimble Inc (NASDAQ:TRMB) was sold by PAINTER ROBERT G on Monday, May 1. VANDE STEEG NICKOLAS sold $1.49M worth of Trimble Inc (NASDAQ:TRMB) on Wednesday, May 10.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.